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Background/aims: Transglutaminase activity has long been implicated in the cataract formation.
However, the precise mechanism of how it is produced and involved in this process remains unclear.
Here the authors sought to examine whether transglutaminase 2 (TGase 2) is expressed in lens epithe-
lial cells from patients with anterior polar cataracts, to determine whether TGase 2 expression is
induced by transforming growth factor (TGF-β) in cultured lens epithelial cells, and to determine
whether TGase 2 participates in the crosslinking of fibronectin in lens epithelial cells in vitro.
Methods: Lens epithelial cells from anterior polar cataracts, nuclear cataracts, and non-cataractous
clear lenses were examined for the expression of TGase 2 using reverse transcription-polymerase chain
reaction, western blot analysis, and immunohistochemical analysis. The modulation of extracellular
TGase 2 activity by TGF-β was measured by the formation of fibronectin polymers and the incorpora-
tion of fluorescein cadaverine into extracellular matrix proteins. The effect of TGase 2 overexpression
was analysed by immunofluorescence staining and western blot analysis of human lens epithelial (HLE)
B-3 cells transiently transfected with TGase 2 gene.
Results: The expression of TGase 2 mRNA and its protein was markedly enhanced in lens epithelial
cells from patients with anterior polar cataracts. Treatment of HLE B-3 cells with TGF-β caused an
increase in TGase 2 protein, its extracellular activity, and the crosslinking of fibronectin. Transient
transfection of HLE B-3 cells with the TGase 2 gene led to the increased production of fibronectin mono-
mers and polymers.
Conclusions: This study shows that TGase 2 is overexpressed in lens epithelial cells from anterior polar
cataracts and that TGF-β may be a causative factor in the induction of TGase 2. The enhanced expres-
sion of TGase 2 might cause the accumulation and crosslinking of the extracellular matrix proteins and
might play a part in anterior polar cataract development.
Anterior polar cataracts are formed by metaplasia of thelens epithelial cells beneath the anterior capsule of thelens. The lens epithelial cells of this region are
transformed into myofibroblast-like cells attached to subcap-
sular plaques of abnormal extracellular matrix molecules.1 2
Transforming growth factor β (TGF-β) has been reported to be
a key modulator in this pathology. In rat lens cultures, TGF-β
induces distinct anterior opacities, and produces fibrotic
plaques consisting of type I collagen and α-smooth muscle
actin.3 4 Moreover, transgenic mice expressing TGF-β under
the αA-crystallin promoter, develop opacities that resemble
the plaques seen in human anterior polar cataracts.5 Analyses
of lens epithelial cells from patients with anterior polar cata-
racts also indicate TGF-β as a key factor in these cataractous
changes.6 Extracellular proteins such as fibronectin, type I col-
lagen, and TGF-β inducible gene-h3 (βIG-H3) have been
detected in clinical specimens from patients with anterior
polar cataracts.6 7
Transglutaminases (TGases) are a Ca2+ dependent family of
enzymes that establish e-(γ-glutamyl) lysine crosslinkages
and aid in the incorporation of polyamines and histamine into
proteins via covalent bonding.8 9 The catalytic action of TGases
results in the formation of an isopeptide bond that is highly
resistant to proteolysis and denaturants. The TGase family is
composed of several members, including plasma factor XIII,
TGase 1 (keratinocyte TGase), TGase 2 (tissue TGase), TGase 3
(epidermal TGase), and TGase 4 (prostate TGase). Among
them, TGase 2 has been most widely identified in many cell
types10 and implicated in diverse physiological functions such
as cell differentiation,11 wound healing,12 and apoptosis.13
TGase 2 can be involved in the crosslinking of both intracellu-
lar and extracellular proteins. For example, TGase 2 appears to
be involved in the crosslinking of intracellular proteins in cells
undergoing apoptotic cell death.13 TGase 2 can also be secreted
onto the surface of the cells and play a key part in the
crosslinking of extracellular matrix proteins.14–16
In this study, we sought to explore more detailed
mechanisms implicated in the abnormal deposition of
extracellular matrix molecules during anterior polar cataract
formation. We speculated that TGase 2 could be an important
pathogenic modulator in the matrix remodelling processes. To
test this, we investigated the expression of TGase 2 in lens epi-
thelial cells from cataract and non-cataract patients. We also
explored whether TGF-β increases the expression of TGase 2
and whether the overexpression of TGase 2 leads to the




Lens capsules attached to lens epithelial cells from patients
were collected and classified by the same surgeon, according
to a modified version of the Lens Opacities Classification Scale
(LOCS)-III grading system. Non-cataractous clear lens cap-
sules were obtained during clear lens extraction for the
correction of high myopia. The ages of the patients with ante-
rior polar cataract were 52–62 years old and 40% were male.
The ages of the patients with nuclear cataract were 60–72
years old and 45% were male. The ages of the control group
were 34–40 years old and 55% were male. The anterior
capsules were removed and placed immediately into TRIzol
reagent (GibcoBRL, Gaithersburg, MD, USA) for RNA
preparation, frozen, and stored at −70°C for protein extraction,
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:












. . . . . . . . . . . . . . . . . . . . . . .
1293
www.bjophthalmol.com
or fixed in neutral buffered formalin for immunohisto-
chemical analysis. The number of specimens used in each
experiment is described in the figure legends. The handling of
human tissue samples complied with the tenets of the Decla-
ration of Helsinki, and consent and proper approval were
obtained before all experiments.
Cell culture and treatment
Human lens epithelial cell line HLE B-3 was kindly provided
by Usha Andley (Washington University School of Medicine,
St Louis, MO, USA), and maintained as described
previously.17 The cultures were allowed to reach 75–80%
confluence and supplemented with 10 ng/ml of TGF-β2, or
TGF-β1 (PeproTech, Rocky Hill, NJ, USA) in serum free
medium. At the indicated time points, the cells were collected
for reverse transcription-polymerase chain reaction (RT-PCR)
or western blot analysis.
Immunohistochemical analysis of tissue sections
Immunohistochemistry was performed as described
previously.7 18 Briefly, anterior lens capsules with attached lens
epithelial cells were fixed, paraffin embedded, and sectioned.
The sections were then incubated with mouse anti-human
TGase 2 antibody (CUB 7402, NeoMarkers, Fremont, CA,
USA). The sections were then incubated in biotinylated goat
anti-mouse IgG (Dako, Carpinteria, CA, USA) and
streptavidin-horseradish peroxidase (HRP), and visualised
according to the manufacturer’s instructions using a detection
kit (LSAB/DAB+ System, Dako). The immunolabelled sec-
tions were counterstained with Meyer’s haematoxylin and
examined with a light microscope. Control experiments were
performed with identical procedures with normal mouse IgG
in place of primary antibody. All experiments were replicated
at least twice.
RNA isolation and RT-PCR
Total cellular RNA was extracted from lens epithelial cells
attached to the anterior capsules of human lenses or cultured
HLE B-3 cells using TRIzol reagent, according to the manufac-
turer’s instructions. Samples of RNA (1 µg of total RNA) was
reverse transcribed and amplified with gene specific primers
using a ThermoScript RT-PCR System kit (GibcoBRL). DNA
size markers were run in parallel to validate the predicted sizes
of the amplified bands (MBI Fermentas, Hanover, MD, USA).
The primer sequences specific for the genes examined and
expected product sizes were as follows: 5’-GATTGGGAA
CTGGTCTGGTG-3’ (sense), 5’-CTGAGCCTTCTGGGTGCTTA-3’
(antisense), for TGase 1 (638 bp), 5’-CGAACCACCTGAA
CAAACTG-3’ (sense), 5’-ATCTCCACCGTCTTCTGCTC-3’ (anti-
sense), for TGase 2 (538 bp), 5’-ATCCCATCACCATCTTCCAG-3’
(sense), 5’-CCTGCTTCACCACCTTCTTG-3’ (antisense), for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 579
bp). The primers were synthesised by GibcoBRL.
Western blot analysis
Total cell lysates were isolated from the lens epithelial cells of
human lens capsules or cultured HLE B-3 cells using lysis
buffer (25 mM HEPES, pH 7.5, 0.3 M NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 0.05% Triton X-100, 0.5 mM DTT, 0.4 mM PMSF
(Sigma, St Louis, MO), 2 µg/ml leupeptin (Sigma), and 2
µg/ml aprotinin (Sigma)). After centrifugation for 10 minutes
at 12 000 g, the supernatant proteins (5 µg/lane) were
subjected to SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (Hybond, Amer-
sham, Piscataway, NJ, USA). To aid transfer of crosslinked
proteins, 75 µg/ml of pronase (Sigma) was added into the
transfer buffer, and the blotting membrane was presoaked in
this buffer before transfer. The membranes were blocked and
incubated with mouse anti-TGase 2 antibody (NeoMarkers),
mouse anti-fibronectin antibody (Sigma), or mouse anti-β-
actin antibody (Sigma) at 1:1000 dilution. These blots were
then reacted with a HRP conjugated anti-mouse secondary
antibody (Amersham). A stripping and reprobing of the
membrane was performed as described in the manufacturer’s
instructions (Amersham). Immunoreactive proteins were
visualised using ECL detection reagents (Amersham) on
autoradiographic films.
Detection of extracellular TGase 2 activity
An in situ TGase2 activity assay was performed as previously
described.19 20 Briefly, HLE B-3 cells were seeded into four well
glass chamber slides (Nunc, Naperville, IL, USA). After reach-
ing 60–65% confluence, cells were washed and incubated in
the presence or absence of 10 ng/ml of TGF-β2 or TGF-β1 for
72 hours. Then, 0.5 mM fluorescein cadaverine (Molecular
Probes, Eugene, OR, USA) was added to the cell culture and
incubated for 15 hours. To inhibit TGase 2 activity, 0.1 mM
monodansylcadaverine (Sigma) was added to the cultures
with TGF-β2. After incubation the cells were washed, fixed in
methanol at −20°C, and mounted. In double staining
experiments, after staining with fluorescein cadaverine and
fixing, cells were blocked with 3% bovine serum albumin
(BSA) in phosphate buffered saline (PBS), incubated with
mouse anti-fibronectin antibody (Sigma) diluted 1:50 in
blocking buffer for 15 hours at 4°C, and then incubated with
rhodamine conjugated (TRITC) anti-mouse IgG (Sigma)
diluted 1:30 in blocking buffer, for 2 hours at room
temperature. Cells were viewed using a confocal laser
microscope (Leica CLSM, Swiss) equipped with an argon
krypton laser set at 488 nm and 560 nm for fluorescein and
rhodamine excitation.
Cloning of TGase 2 gene
TGase 2 cDNA was obtained by nested polymerase chain reac-
tion (PCR) amplification using a human fibroblast cDNA
library (Clontech, Palo Alto, CA, USA). The first PCR was per-
formed with PCR primers located between 72 and 2388 bp of
the human TGase 2 gene, where the 3’ primer is close to the
poly (A) tail: 5’-CCTCCTTAAAGCATAAATCTC-3’ (sense),
5’-TTAGGCGGGGCCAATGATGAC-3’ (antisense). The PCR
product was purified using a PCR purification kit (Qia quick,
Qiagen, Valencia, CA, USA), and used as template for the sec-
ond PCR. The construct of human TGase 2 gene was designed
to be inserted into the pIND (SP1) expression vector (Invitro-
gen, San Diego, CA, USA). The second set of PCR primers was
designed with an extension of extranucleotides containing the
restriction enzyme sites of EcoRI at the 5’ end and XhoI at the
3’ end: 5’-agtaaaGAATTCATGGCCGAGCTGGTCTTAGAGAGGT
GTGATCTG-3’ (sense, EcoRI), 5’-gaatcaGAGCTCTTATCAAATG
ATGACATTCCGGAAGCCCTT-3’ (antisense, XhoI). The PCR
conditions used were: 95°C for 4 minutes, and 30 cycles of
95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1
minute. The PCR products were purified using a PCR purifica-
tion kit, and digested with EcoRI and XhoI. The full length
human TGase 2 gene was ligated into the expression vector,
transformed, and sequenced to verify the amplification
efficacy.
Immunofluorescence staining of extracellular TGase 2
and fibronectin in cells transiently transfected with
TGase 2 gene
For transient transfection of HLE B-3 cells with TGase 2 gene,
TGase 2 cDNA in pIND was digested with EcoRI and XhoI, and
then subcloned into the eukaryotic expression vector pcDNA
3.1(+) (Invitrogen) at EcoRI-XhoI sites. HLE B-3 cells were
transfected with pcDNA 3.1(+)-TGase 2 or pcDNA 3.1(+) as
a control, using the FuGENE 6 transfection reagent (Roche
Diagnostics, Indianapolis, IN, USA) as described in the manu-
facturer’s instruction. Briefly, 1 × 105 cells were plated per well
of a six well culture dish and transfected with 1 µg of pcDNA
3.1(+)-TGase 2 or pcDNA 3.1(+). After 72 hours, cells were
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either immunofluorescence stained or collected for western
blot analysis. The double immunofluorescence staining proce-
dure was performed as described above.
RESULTS
Increased expression of TGase 2 in lens epithelial cells
from patients with anterior polar cataracts
To determine whether TGase 2 expression may be implicated
in human anterior polar cataracts, we compared the levels of
TGase 2 mRNA in lens epithelial cells from anterior polar
cataracts with those from nuclear cataracts and non-
cataractous clear lenses. As shown in Figure 1A, the
expression of TGase 2 mRNA was markedly enhanced in the
lens epithelial cells of anterior polar cataracts. Meanwhile, the
expression of TGase 1, which has been detected in the corneal
epithelium,21 was not detectable in any specimen. The amount
of GAPDH product, an internal housekeeping control for PCR
amplification, was similar in all specimens.
To confirm the expression of the corresponding proteins, we
extracted cell lysates from the lens epithelial cells attached to
the anterior capsules and performed western blot analysis. As
shown in Figure 1B, a single band for TGase 2 at
approximately 84 kDa was detected. The results correlated
with the RT-PCR data, and demonstrated a significantly higher
expression of TGase 2 in lens epithelial cells from anterior
polar cataracts than that in lens epithelial cells from nuclear
cataracts or non-cataractous clear lenses. Quantification of
each band by densitometric scanning using seven specimens
for each type of patient also showed that there was a
significantly increased expression of TGase 2 in lens epithelial
cells from the patients with anterior polar cataracts (Fig 1C).
We also tested TGase 2 expression in clinical samples using
immunohistochemical analysis. As shown in Figure 1D, in the
subcapsular plaques of the anterior polar cataracts, lens
epithelial cells surrounded by extracellular matrices were
positive for TGase 2 (Fig 1D, panel B). By comparison, TGase 2
was barely detectable in lens epithelial cells obtained from
nuclear cataracts (Fig 1D, panel A) or non-cataractous clear
lenses (data not shown). Sections incubated without primary
antibody showed no reactivity (data not shown). These results
were in agreement with the RT-PCR and western blot data.
Enhanced expression of TGase 2 in cultured lens
epithelial cells treated with TGF-β
TGF-β has shown to be a key modulator in anterior polar cata-
ract formation.4 5 We, therefore, examined whether TGF-β2
can increase the expression of TGase 2 in lens epithelial cells.
As shown in Figure 2A, the expression of TGase 2 protein was
substantially increased in a time dependent manner after
treating HLE B-3 cells with 10 ng/ml of TGF-β2. The increased
levels were maintained for 3–4 days. Two days after treatment
with different concentrations of TGF-β2, the expression of
TGase 2 protein was detected even at the concentration as low
as 0.1 ng/ml, and increased in a dose dependent manner (Fig
2B). A plateau was reached at 10 ng/ml. The expression of
TGase 2 mRNA was also increased in time and dose dependent
manners in cells treated with TGF-β2 (data not shown). Simi-
lar effects were observed after treatment of HLE B-3 cells with
TGF-β1 (data not shown).
Increased extracellular TGase 2 activity by TGF-β2 and
its inhibition by monodansylcadaverine
In previous reports, TGase 2 activity was visualised in situ by
incorporation of a specific substrate, fluorescein
cadavarine.19 20 Fluorescein cadaverine is believed to act as a
Figure 1 Enhanced expression of TGase 2 in human anterior polar
cataracts. (A) Total cellular RNA was isolated from lens epithelial
cells of patients with nuclear cataracts (lane 1), non-cataractous clear
lenses (lane 2), and anterior polar cataracts (lane 3). The levels of
mRNAs for GAPDH, TGase1, and TGase2 were examined by
RT-PCR. The data shown are from one of three independent assays
that produced similar results. M = molecular size standards (in base
pairs). (B) Cell lysates were prepared from lens epithelial cells
attached to the anterior capsules, and then the levels of TGase 2
proteins were assessed by western blot analysis. After separating
proteins by SDS-PAGE, the whole gel was immunoprobed. β-actin
was used as the loading control indicator. C = nuclear cataracts
(lane 1); N = non-cataractous clear lenses (lane 2); APC = anterior
polar cataracts (lane 3). (C) Proteins were quantified using a
bioimaging analyser (Bio-Rad Imaging System, Bio-Rad, Hercules,
CA, USA), and expressed in arbitrary units. Each displayed value
was normalised against the density of the respective band of β-actin,
and the displayed values in this graph represents the mean value
(SD) of samples from seven patients (*p<0.05). (D) Anterior lens
capsules with attached lens epithelial cells from patients with anterior
polar cataracts (panel B), and nuclear cataracts (panel A) were
assayed immunohistochemically for TGase2 expression (brown
colour) (original magnification, ×400). The capsules of anterior polar
cataracts were thinner than those in nuclear cataracts, as previously
reported.7 The data presented were from one of six independent
assays that produced similar results. LC = lens capsule; LE = lens epi-
thelial cells (arrow); SP = subcapsular plaque; MF = myofibroblast-
like lens epithelial cells (arrowheads).
Figure 2 Enhanced expression of TGase 2 by TGF-β2 in cultured
HLE B-3 cells. Cells were seeded in 100 mm culture dishes coated
with collagen type IV (10 µg/ml, Sigma) at 1.0 × 106 cells/dish.
Time and dose responses of the induction of TGase 2 in lens
epithelial cells treated with TGF-β2. (A) Time response: cells
incubated with 10 ng/ml of TGF-β2 in serum free medium were
harvested at the indicated time intervals and subjected to western
blot analysis. (B) Dose response: after incubation with various
concentrations of TGF-β2 for 48 hours, cells were extracted for
western blot analysis. Results were representative of three repeated
experiments.
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competitive primary amine to the peptide bound e-amino
lysine group, and becomes incorporated into endogenous
γ-glutamyl residues if active TGase 2 is present. In order to
determine whether the increased crosslinking of fibronectin
by TGF-β may be correlated with increase in TGase 2 activity,
HLE B-3 cells treated with or without TGF-β2 were cultured in
the presence of fluorescein cadaverine and examined by con-
focal laser microscopy.
As shown in Figure 3, after treatment with TGF-β2, cells
exhibited a large number of fluorescein cadavarine punctuate
patches on the surface of the cells, indicating enhanced TGase
2 activity (Fig 3D). A much weaker staining pattern was
observed in non-treated control cells (Fig 3A). Antibody to
fibronectin revealed very few fibronectin fibrils in non-treated
control cells (Fig 3B). Abundant fibrils were observed on the
surface of the cells treated with TGF-β2 (Fig 3E). Superim-
posed images depicted the increased co-localisation of
fluorescein cadaverine and fibronectin in cells treated with
TGF-β2 (Fig 3F) compared to non-treated control cells (Fig
3C). This indicated that TGase 2 might be directly involved in
the crosslinking of fibronectin. The addition of monodansylca-
daverine, a selective irreversible inhibitor for TGase 2, to the
cells treated with TGF-β2, led to a considerable reduction in
incorporation of fluorescein cadaverine (Fig 3G), fibril forma-
tion of fibronectin (Fig 3H), and their co-localisation (Fig 3I).
Similar effects were observed after treating cells with TGF-β1
(data not shown).
Enhanced expression and crosslinking of fibronectin in
HLE B-3 cells transiently transfected with TGase 2 gene
Results shown in Figure 3 indicated that TGase 2 might be
directly involved in the crosslinking of fibronectin in response
to TGF-β. To further investigate this possibility, TGase 2 gene
was transiently overexpressed in HLE B-3 cells. Double
immunofluorescence staining procedure for cadaverine and
fibronectin labelling was performed 72 hours after cells were
transfected with the human TGase 2 gene. As shown in Figure
4A, extracellular activity of TGase 2 protein was clearly
increased in cells transfected with TGase 2 gene (Fig 4A, panel
D), but barely visible in control cells transfected with the vec-
tor alone (Fig 4A, panel A). Moreover, when these cells were
co-stained with fibronectin antibody, cells transfected with
TGase 2 gene showed a significantly enhanced staining (Fig
4A, panel E) compared with control cells (Fig 4A, panel B).
Superimposed images depicted the increased co-localisation
of fluorescein cadaverine and fibronectin in cells transfected
with TGase 2 gene (Fig 4A, panel F) compared to control cells
transfected with the vector alone (Fig 4A, panel C). This was
further confirmed by western blot analysis. As shown in Fig-
ure 4B increased amounts of fibronectin monomers and poly-
mers were detected from the lysates of cells transfected with
Figure 3 Double immunofluorescence analysis of in situ TGase 2 activity, as shown by TGase 2 mediated fluorescein cadaverine (green)
incorporation and fibronectin (red) fibril formation (original magnification ×800). The co-localisation of fluorescein cadaverine and fibronectin
resulted in a bright yellow mixed colour by double filter analysis. In non-treated control cells, fluorescein cadaverine (A) and fibronectin (B)
were sparse, and only very small yellow spots were observed between the cells after pictures were superimposed (C). In TGF-β treated cells, the
staining for fluorescein cadaverine (D) and fibronectin (E) were markedly augmented and prominent yellow spots were visible between the cells
(F), indicating an increase in the co-localisation of fluorescein cadaverine and fibronectin. After treating the TGF-β2 treated cells with
monodansylcadaverine, the staining of fluorescein cadaverine (G), fibronectin fibrils (H), and co-localisation (I) was markedly decreased.
Arrows point to areas of high TGase 2 activity, where fibronectin fibrils are also co-localised.
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TGase 2 gene (lane 2) compared to those of control cells (lane
1). This indicated that the increased expression of fibronectin
monomers and the crosslinking of fibronectin were coincident
with the overexpression of TGase 2 in lens epithelial cells.
DISCUSSION
The aberrant accumulation of extracellular matrix proteins,
such as fibronectin and type I collagen, has been previously
demonstrated in anterior polar cataracts. TGF-β has been con-
sistently shown as a prime factor implicated in this pathologi-
cal process.4–6 However, the precise mechanism as to how
TGF-β establishes the irreversible abnormal extracellular
matrix deposits in anterior polar cataracts remains to be
explored.
TGase 2 has been detected in various ocular tissues, includ-
ing the ciliary body, iris, conjunctiva, and trabecular mesh-
work, where it might stabilise structural proteins and
extracellular matrix-cell interactions.21–23 In the lens, the pres-
ence of TGase 2 in non-cataractous lens epithelial cells has
been reported previously.21 22 Our RT-PCR and western blot
analyses showed limited expression of TGase 2 in non-
cataractous lens epithelial cells. TGase has also been impli-
cated in cataract formation. In senile cataracts, considerably
higher TGase activity was found in the lens cortex,24 25 with
β-crystallin and vimentin having been identified as possible
substrates.26–28 Previous studies have also demonstrated that
TGase 2 can bind several extracellular matrix proteins in other
cell types.29–32 Martinez et al reported that cell surface TGase 2
can mediate the crosslinking of fibronectin in human umbili-
cal vein endothelial cells.33 In this study, we demonstrated that
the expression of TGase 2 was significantly increased in lens
epithelial cells from anterior polar cataracts. This suggests that
overexpression of TGase 2 may be involved in the crosslinking
of extracellular matrix proteins, such as fibronectin, seen in
anterior polar cataracts.
TGF-β has been reported to induce the expression of TGase
2 in various cells including rabbit tracheal epithelial cells,
human epidermal keratinocytes, and rat hepatoma cell
lines.34–36 Notably, in the eye TGF-β induces the expression of
TGase 2 and the crosslinking of fibronectin in human
trabecular meshwork.23 We showed that TGF-β induced the
overexpression of TGase 2 and the crosslinking of fibronectin
in human lens epithelial cells. This result adds TGase 2 to the
group of genes that is increased by TGF-β in lens epithelial
cells. We also observed that TGF-β induced crosslinking of
fibronectin was significantly reduced by TGase 2 inhibitor and
that an increased crosslinking of fibronectin was observed in
lens epithelial cells transfected with TGase 2 gene. These
results suggest that TGase 2 mediates the TGF-β induced for-
mation of fibronectin polymers and that the overexpression of
TGF-β and TGase 2, and the aberrant accumulation of
extracellular matrix proteins in anterior polar cataracts are
pathologically coordinated.
Secreted TGF-β is non-covalently associated with latency
associated peptide (LAP), in a biologically inactive form.37 This
complex is secreted as part of a larger latent complex in which
latent binding protein (LTBP) is linked to LAP via disulphide
bonds.38 Recent reports suggested that TGase 2 might enhance
the conversion of latent TGF-β to active TGF-β. This
conversion may in turn stimulate the expression of TGF-β
mRNA by an autocrine mechanism.39–41 It has also been
proposed that matrix association of LTBP-1, a critical step in
the activation of latent TGF-β, is TGase 2 dependent.39–41 Inter-
estingly, our results showed that transient transfection of lens
epithelial cells with TGase 2 gene stimulated increased levels
of fibronectin polymers and increased expression of fibro-
nectin monomers (Fig 4). According to our preliminary data,
HLE B-3 cells in the absence of any stimulators exhibited sub-
stantial expression of TGF-β mRNA (data not shown). Taken
together, the results imply that TGase 2 might function to
convert latent TGF-β to active TGF-β, which could further
augment fibronectin expression and accelerate development
of fibrotic plaques. In support of this notion, the elevated level
of TGF-β mRNA has previously been documented in lens epi-
thelial cells from patients with anterior polar cataracts.6
Further investigations are needed to test whether TGase 2
increases the amount of active TGF-β in lens epithelial cells.
In conclusion, we report for the first time that lens epithe-
lial cells of human anterior polar cataracts overexpress TGase
2. The elevation of TGase 2 might be important in covalent
crosslinking of extracellular matrix protein such as fibro-
nectin, which might render them less accessible to matrix
degrading proteases or other degradative agents. This could
reduce the turnover of these matrices and contribute to the
persistence of subcapsular plaques.
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